- Don't ask 'are peptides good' — ask about a specific peptide against specific criteria.
- Evaluate on four axes: evidence tier, regulatory status, sourcing, and risk profile.
- Established drugs and unverified research chemicals are not in the same category.
- The framework narrows the question; a clinician answers it.
"Should I use peptides?" is the wrong question — it's too broad to answer. Here's a framework that turns it into questions you can actually evaluate.
Axis 1: evidence tier
Where does this specific peptide sit? At one end are rigorously tested, approved drugs — 80+ of them (Wang et al., Signal Transduction and Targeted Therapy). At the other end are compounds with little human data. Place your candidate honestly on that spectrum before anything else.
Axis 2: regulatory status
Is it an approved medication, an off-label use, or an unapproved research chemical? These carry completely different risk and legality profiles. The peptide field is a century-old regulated science (Muttenthaler et al., Nature Reviews Drug Discovery) — but plenty of what's sold online sits outside that.
Axis 3: sourcing
Purity and identity are everything for a molecule that has to bind a receptor precisely. Unverified sourcing undermines any potential benefit and adds real risk (Muttenthaler et al.). If you can't verify it, treat that as a red flag.
Axis 4: risk profile
What's the downside, including interactions with your health conditions and other compounds? This is exactly where a professional adds value you can't replicate with research.
Where the framework ends
This narrows "should I?" into answerable questions — but the final call belongs with a licensed clinician who can weigh your specifics. The framework is for thinking clearly, not for self-prescribing.
Key takeaways
- Evaluate a specific peptide, not 'peptides' in general.
- Four axes: evidence, regulation, sourcing, risk.
- Approved drugs ≠ unverified research chemicals.
- Framework clarifies; a clinician decides.
